← All indications
Penile Neoplasms
Cancers or tumors of the PENIS or of its component tissues.
Drugs by status
Phase 3 trials (1)
Phase 2 trials (44)
- ino-3112
- dacomitinib
- afatinib
- atezolizumab
- avelumab
- irinotecan
- durvalumab
- e6 tcr
- e7 tcr transduced pbl cells
- entinostat
- paclitaxel
- aldesleukin
- nivolumab
- pembrolizumab
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- nimotuzumab
- niraparib
- pazopanib
- ifosfamide
- ipilimumab
- carboplatin
- interleukin-12
- cyclophosphamide
- dostarlimab
- vinflunine
- vorinostat
- cabazitaxel
- cabozantinib
- young tumor infiltrating lymphocytes
- enfortumab vedotin
- +14 more
Phase 1 trials (19)
Organizations
Organization Involved with Phase 2 Indications (44)
- Incyte
- Bristol-Myers Squibb
- Roche
- AstraZeneca
- Merck
- Pfizer
- Sanofi
- Inovio Pharmaceuticals
- Biontech
- The EMMES Corporation
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Cancer Institute, France
- AIDS Malignancy Consortium
- Cancer Biotherapy Research Group
- University of London
- Harvard University
- Eastern Cooperative Oncology Group
- Hoag Memorial Hospital Presbyterian
- Hoosier Cancer Research Network
- Latin American Cooperative Oncology Group
- MedSIR
- Oregon Health and Science University
- Southwest Oncology Group
- UNICANCER
- University of Milan
- University of Toronto
- University of Bristol
- University of California, San Francisco
- University of Amsterdam
- +14 more
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (1)